プロモーションスケジュール Carmell Therapeutics Corporation
詳細なスケジュール
簡易グラフ
会社について
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
| EBITDA |
-0.0017 |
| EV/EBITDA |
-5.82 |
| IPO date |
2023-07-17 |
| ISIN |
US1429221039 |
| Industry |
Biotechnology |
| P/BV |
1.7 |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Выручка |
0.0037 |
| Сайт |
https://www.carmellrx.com
|
| Цена ао |
2.9 |
| Число акций ао |
0.01102 млрд |
| 1日あたりの価格変動: |
+5.71% (0.35) |
| 週ごとの価格変動: |
-0.8043% (0.373) |
| 月ごとの料金変更: |
-33.81% (0.559) |
| 3ヶ月間の価格変動: |
-77.84% (1.67) |
| 半年間の価格変動: |
-86.27% (2.695) |
| 年間の価格変動: |
-87.67% (3) |
| 年初からの価格変動: |
-86.59% (2.76) |
|
|
過小評価
| 名前 |
意味 |
学年 |
| P/S |
0 |
0 |
| P/BV |
1.71 |
8 |
| P/E |
0 |
0 |
| EV/EBITDA |
-8.18 |
0 |
| 合計: |
|
4.63 |
|
効率
| 名前 |
意味 |
学年 |
| ROA, % |
-24.15 |
0 |
| ROE, % |
-62.41 |
0 |
| 合計: |
|
0 |
|
|
|
配当金
| 名前 |
意味 |
学年 |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| 合計: |
|
0 |
|
義務
| 名前 |
意味 |
学年 |
| Debt/EBITDA |
-0.4195 |
10 |
| 合計: |
|
10 |
|
成長の衝動
| 名前 |
意味 |
学年 |
| 収益性 Revenue, % |
0 |
0 |
| 収益性 Ebitda, % |
37.63 |
5 |
| 収益性 EPS, % |
316.09 |
10 |
| 合計: |
|
7 |
|
| スーパーバイザー |
役職 |
支払い |
生年 |
| Mr. Rajiv Sarman Shukla |
Executive Chairman |
292.19k |
1975 (49 年) |
| Dr. Phil Campbell Ph.D. |
Founder and Chief Scientific Officer |
N/A |
|
| Dr. Lee Weiss Ph.D. |
Founder |
N/A |
|
| Dr. James Burgess M.D. |
Founder |
N/A |
|
| Mr. Bryan J. Cassaday |
Chief Financial Officer |
261.7k |
1969 (55 年) |
| Ms. Kendra Bracken-Ferguson |
Chief Executive Officer |
|
|
